14,816 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Royal Fund Management LLC

Royal Fund Management LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,816 shares of the biopharmaceutical company’s stock, valued at approximately $1,200,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. OFI Invest Asset Management acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $33,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on GILD shares. Royal Bank of Canada lowered their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research note on Wednesday, April 24th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, TD Cowen lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $83.69.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Down 0.8 %

GILD traded down $0.55 during mid-day trading on Friday, reaching $64.78. 7,822,720 shares of the stock were exchanged, compared to its average volume of 7,345,331. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The stock has a market capitalization of $80.66 billion, a PE ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a 50 day moving average price of $70.55 and a two-hundred day moving average price of $75.83. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.37 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.